BR0116994A - Um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (fdc) de quatro drogas antituberculose - Google Patents

Um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (fdc) de quatro drogas antituberculose

Info

Publication number
BR0116994A
BR0116994A BR0116994-7A BR0116994A BR0116994A BR 0116994 A BR0116994 A BR 0116994A BR 0116994 A BR0116994 A BR 0116994A BR 0116994 A BR0116994 A BR 0116994A
Authority
BR
Brazil
Prior art keywords
fdc
composition
improved process
fixed dose
preparing
Prior art date
Application number
BR0116994-7A
Other languages
English (en)
Inventor
Himadri Sen
Kour Chand Jindal
Kishor Dattatray Deo
Krishnakant Tulsiram Gandhi
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR0116994A publication Critical patent/BR0116994A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"UM PROCESSO APERFEIçOADO PARA A PREPARAçãO DE UMA COMPOSIçãO QUE ABRANGE UMA COMBINAçãO DE DOSE FIXA (FDC) DE QUATRO DROGAS ANTITUBERCULOSE". A saber a rifampicina, a isoniazida, a pirazinamida e o cloridrato de etambutol, o qual melhora a dissolução da droga rifampicina, de baixa solubilidade, e assim melhora sua biodisponibilidade. Proporciona ainda um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (FDC) de quatro drogas antituberculose, a saber a rifampicina, a isoniazida, a pirazinamida e o cloridrato de etambutol, o qual melhora a dissolução da droga rifampicina, de baixa solubilidade, e assim melhora sua biodisponibilidade sem, no entanto, usar qualquer agente surfactante.
BR0116994-7A 2001-04-27 2001-04-27 Um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (fdc) de quatro drogas antituberculose BR0116994A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2001/000093 WO2002087547A1 (en) 2001-04-27 2001-04-27 An improved process for preparation of four-drug anti-tubercular fixed dose combination

Publications (1)

Publication Number Publication Date
BR0116994A true BR0116994A (pt) 2004-03-02

Family

ID=11076344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116994-7A BR0116994A (pt) 2001-04-27 2001-04-27 Um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (fdc) de quatro drogas antituberculose

Country Status (2)

Country Link
BR (1) BR0116994A (pt)
WO (1) WO2002087547A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
EP1711182A1 (en) * 2004-02-04 2006-10-18 Vinay Ramakant Sapte Oral cyclodextrin complexes of antituberculosis drugs
WO2005107740A1 (en) * 2004-05-07 2005-11-17 Vinay Ramakant Sapte Enhancing the efficacy of tubercular drugs by combination with alpha tocopherol
WO2005107741A1 (en) * 2004-05-07 2005-11-17 Vinay Ramakant Sapte Novel oral compositions comprising antitubercular drugs in combination with alpha-tocopherol
US8604222B2 (en) 2004-07-30 2013-12-10 Forest Laboratories Holdings Limited Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
RU2423977C1 (ru) * 2010-04-20 2011-07-20 Открытое Акционерное Общество "Фармасинтез" Противотуберкулезное лекарственное средство на основе 4-тиоуреидоиминометилпиридиния перхлората, способ его получения и способ лечения
FR2963236B1 (fr) * 2010-07-28 2013-03-01 Pharma 5 Lab Procede de preparation d'une composition pharmaceutique contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et eventuellement l'ethambutol
WO2012013756A2 (fr) 2010-07-28 2012-02-02 Laboratoires Pharma 5 Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et éventuellement l'ethambutol
US8470365B2 (en) 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
CN102727496A (zh) * 2011-04-12 2012-10-17 上海双健现代药物技术咨询有限公司 一种复方抗结核药口服固体制剂及其制备方法
CN102579447B (zh) * 2011-12-31 2014-10-15 沈阳药科大学 抗结核药物复方制剂的制备方法
CN102920707B (zh) * 2012-11-02 2014-10-29 沈阳药科大学 一种复方抗结核制剂的制备工艺
RU2672879C2 (ru) * 2013-07-26 2018-11-20 Санофи Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения
JP2016539110A (ja) * 2013-07-26 2016-12-15 サノフイ イソニアジドの顆粒およびリファペンチンの顆粒を含む分散性錠剤の形態の抗結核性の安定な医薬組成物ならびにその製造方法
SG11201510730UA (en) * 2013-07-26 2016-01-28 Sanofi Sa Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
CN104706638A (zh) * 2015-02-04 2015-06-17 上海华源安徽仁济制药有限公司 一种复方利福平胶囊及其制备方法
EP3578167A1 (en) * 2018-06-04 2019-12-11 Universitat de Barcelona Suspension formulation for the treatment of tuberculosis
CN110169954B (zh) * 2019-06-20 2021-10-15 江苏四环生物制药有限公司 一种溶出稳定的吡嗪酰胺片及其制备方法
CN110200933A (zh) * 2019-07-11 2019-09-06 重庆华邦制药有限公司 用于制备治疗肺结核的三联复方制剂的组合物及其制备方法和应用
CN113694067B (zh) * 2021-09-30 2023-12-01 齐齐哈尔医学院 一种共载异烟肼和利福平的微球缓释制剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3916417A1 (de) * 1989-05-19 1990-11-22 Saarstickstoff Fatol Gmbh Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid als aktive wirkstoffe
IT1289883B1 (it) * 1996-10-09 1998-10-19 Lupin Lab Ltd Composizione farmaceutica antitubercolare e procedimento per la sua produzione

Also Published As

Publication number Publication date
WO2002087547A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
BR0116994A (pt) Um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (fdc) de quatro drogas antituberculose
YU75903A (sh) Tiohidantoini i njihovo korišćenje u lečenju dijabetisa
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
CY1106150T1 (el) Μεθοδοι παρασκευης οπτικως καθαρης (r)- και (s)-διδεσμεθυλοσιβουτραμινης
AU2002316811A1 (en) Stable formulation of modified glp-1
ATE513541T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin
HK1028548A1 (en) Formulations for hydrophobic pharmaceutical agents
GEP20043287B (en) Pharmaceutical Composition Containing Fenofibrate and Method for Its Production
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
MXPA04003569A (es) Mezclas bifasicas de glp-1 e insulina.
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
ATE401890T1 (de) Formulierung mit kontrollierten freisetzung enthaltend lamotrigin
JP2002510633A5 (pt)
WO2000032186A3 (en) Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
PL376176A1 (en) Solid preparation
EP1558931A4 (en) ANALYSIS OF PHARMACEUTICAL SOLUBILITY AND STABILITY
IL152074A0 (en) Pharmaceutical preparations and their manufacture
MXPA05012955A (es) Composiciones farmaceuticas de atorvastatina.
WO2002070014A8 (en) Compositions comprising an o/w emulsion containing conjugated linoleic acid
ES2194129T3 (es) Compuestos farmaceuticos.
GEP20043377B (en) Pharmaceutical Complex
ECSP045232A (es) Forma de dosificación oral, procedimiento para prepararla y uso de una base débil farmacéuticamente aceptable o una sal o solvato farmacéuticamente aceptable de la misma para preparar dicha forma de dosificación oral

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA(S) 3A ANUIDADE(S), DE ACORDO COM A TABELA VIGENTE, REFERENTE A(S) GUIA(S) NO 300240362232 E COMPROVAR O RECOLHIMENTO REFERENTE A RESTAURACAO DA 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]